Allergan, Inc Discloses issuance of patent on Jan 21 from the USPTO - filing
- On January 21, 2014, the United States Patent and Trademark Office (the USPTO) issued U.S. patent number 8,633,162 (the 162 Patent), covering a method of use relating to the Restasisproduct. On January 21, 2014, the Company submitted the 162 Patent for listing in the Orange Book. The 162 Patent will expire in August 2024.
- On January 21, 2014, Allergan, Inc. (the Company) received a notice letter dated January 14, 2014 (the Notice Letter) from Watson Laboratories, Inc. (Watson) stating that Watson has filed an Abbreviated New Drug Application containing a Paragraph IV patent certification with the U.S. Food and Drug Administration (the FDA) seeking approval to market a generic version of the Companys Restasis(cyclosporine ophthalmic emulsion) 0.05% product. The Notice Letter states that the Paragraph IV patent certification was made with respect to U.S. patent number 8,629,111 (the 111 Patent), covering the Companys specific formulation of the Restasisproduct, which is listed in the FDAs Approved Drug Products With Therapeutic Equivalence Evaluations, commonly known as the Orange Book. The 111 Patent will expire in August 2024. The Company is currently evaluating the Notice Letter and intends to vigorously enforce its intellectual property rights relating to the Restasisproduct, including the 111 Patent.